VERTEX PHARMAC. DL-,01/ US92532F1003 /
2024-11-11 8:58:53 PM | Chg. -13.0500 | Volume | Bid9:59:51 PM | Ask9:59:51 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
471.5500EUR | -2.69% | 22 Turnover: 10,542.0500 |
-Bid Size: - | -Ask Size: - | 120.84 bill.EUR | - | - |
Assets
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Property and Equipment | 789.4370 | 812.0050 | 758.0850 | 958.5340 | 1,094.1000 | ||||||
Intangible Assets | 29 | - | 400 | 400 | 400 | ||||||
Long-Term Investments | 20.4470 | - | - | - | - | ||||||
Fixed Assets | 897.0510 | 2,402.7890 | 3,495.6360 | 3,618.4290 | 3,871.9000 | ||||||
Inventories | 111.8300 | 124.3600 | 167.5020 | 280.7770 | 353.1000 | ||||||
Accounts Receivable | 281.3430 | 409.6880 | 633.5180 | 885.3520 | 1,136.8000 | ||||||
Cash and Cash Equivalents | 1,665.4120 | 2,650.1340 | 3,109.3220 | 5,988.1870 | 6,795 | ||||||
Current Assets | 2,648.9630 | 3,843.1090 | 4,822.8290 | 8,133.3790 | 9,560.6000 | ||||||
Total Assets | 3,546.0140 | 6,245.8980 | 8,318.4650 | 11,751.8080 | 13,432.5000 |
Liabilities
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Accounts Payable | 73.9940 | 110.9870 | 87.6100 | 155.1390 | 195 | ||||||
Long-term debt | 583.9020 | 581.5500 | 538.5760 | 539.0420 | 509.8000 | ||||||
Liabilities to Banks | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
Provisions | 6.3000 | - | - | - | - | ||||||
Liabilities | 1,503.7080 | 1,810.6950 | 2,233.2210 | 3,064.9930 | 3,332.5000 | ||||||
Share Capital | 2.5120 | 2.5460 | 2.5890 | 2.5990 | 2.5000 | ||||||
Total Equity | 2,042.3060 | 4,435.2030 | 6,085.2440 | 8,686.8150 | 10,100 | ||||||
Minority Interests | 13.7270 | 0.0000 | 0.0000 | 0.0000 | - | ||||||
Total liabilities equity | 3,546.0140 | 6,245.8980 | 8,318.4650 | 11,751.8080 | 13,432.5000 |
Income Statement
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 2,488.6520 | 3,047.5970 | 4,162.8210 | 6,205.6830 | 7,574.4000 | ||||||
Depreciation (total) | 61.3970 | 72.4200 | 106.9410 | 109.5150 | 125.6000 | ||||||
Operating Result | 123.2430 | 635.1500 | 1,197.5660 | 2,856.2900 | 2,782.1000 | ||||||
Interest Income | 57.5500 | 34.1190 | - | - | 61.5000 | ||||||
Income Before Taxes | -15.6890 | 600.2410 | 1,394.9190 | 3,116.7980 | 2,730.4000 | ||||||
Income Taxes | -107.3240 | -1,486.8620 | 218.1090 | 405.1510 | 388.3000 | ||||||
Minority Interests Profit | 171.8490 | 9.7930 | 0.0000 | 0.0000 | - | ||||||
Net Income | 263.4840 | 2,096.8960 | 1,176.8100 | 2,711.6470 | 2,342.1000 |
Per Share
Cash Flow
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Cash Flow from Operating Activities | 844.9420 | 1,270.2860 | 1,569.3300 | 3,253.5050 | 2,643.5000 | ||||||
Cash Flow from Investing Activities | -437.6810 | -202.1580 | -1,235.3180 | 99.3880 | -340.9000 | ||||||
Cash Flow from Financing | 68.4040 | -71.2190 | 126.7730 | -505.2810 | -1,478 | ||||||
Decrease / Increase in Cash | 481.4670 | 990.7270 | 462.4280 | 2,868.1640 | 811.2000 | ||||||
Employees | 2,300 | 2,500 | 3,000 | 3,400 | 3,900 |